EVO Stock — Evotec SE

Up next

Next earnings call

Dec 25, 2026 Est · unconfirmed · in 6 wks

Q3 2026 earnings call transcript

call held Nov 5, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 5

Earnings call

Vertex deal confirmed as Q3 nears break-even

EvoTech reported Q3 2026 revenue of €164.9 million and adjusted EBITDA of minus 1.6 million euros, near break-even. Vertex Pharmaceuticals selected EvoTech for commercial manufacturing, and 2026 revenue and adjusted ABDA are expected toward the upper end of guidance ranges.

5 source passages

Science is at the core of EvoTech. Looking at our income statement on slide 7, group revenues for the third quarter of 2026 amounted to €164.9 million, broadly stable compared with €163.9 million in the prior year period. Turning to profitability, adjusted group EBITDA improved significantly in Q3 to minus 1.6 million euros from minus 15 million euros in the prior year quarter, bringing the group close to break even. We’re excited to confirm that Vertex Pharmaceuticals has selected us. We reaffirm our full year 2026 guidance and, based on our current visibility, expect revenue and adjusted ABDA to land toward the upper end of their respective ranges. Open the document at this passage

Nov 5

Current report 6-K

Revenue falls 13.1%, but full-year guidance is reaffirmed

Evotec SE reported nine-month 2026 revenue of €465.0 million, down 13.1% from €535.1 million, while reaffirming full-year 2026 revenue guidance of €570 to €610 million and adjusted Group EBITDA of -€105 to -€70 million. Horizon transformation is ahead of plan.

4 source passages

Group revenue decreased by 13.1% to € 465.0 m (9M 2025: € 535.1 m) while remaining well above expectations implied by Q3 consensus estimates and consistent with FY 2026 guidance range Group revenues expected in the range of € 570 – 610 m (€ 595 – 635 m CER; 2025: € 788.4 m) Adjusted Group EBITDA is expected to reach € (70) – (105) m (€ (60) – (90) m CER; 2025: € 41.1 m) Horizon is progressing slightly ahead of schedule, supporting the delivery of the previously communicated plan to realize 20–30% of the € 75 m run-rate savings from 2027 into 2026. Open the document at this passage

Oct 15

Current report 6-K

Current report

Evotec SE appointed Dr. Joanna Holbrook Chief Scientific Officer and Management Board member effective November 1, 2026; Government of Abu Dhabi’s indirect voting stake fell from 5,62 % to 0,00 % on 09/10/2026.

Oct 14

Current report 6-K

Current report

Evotec SE expects first nine months of 2026 revenue of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million, above market expectations, and reaffirms full-year 2026 guidance.

Sep 29

Current report 6-K

Current report

Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026 by mutual consent; he has served since 2010, and the search for his replacement is ongoing.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

-1.1%

Year over year

Operating margin

-7.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.1%

Year over year · more shares

Price change (1Y)

-50.2%

Trailing year

Short interest

0.0%

Latest settlement · 1.0 days to cover

View all 125 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −35%

below

Price vs 50-day avg −1%

below

RSI (14) 48

neutral

MACD trend Positive

52-week position 9%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +14%

trailing

6-month return −46%

trailing

YTD return −49%

this year

Relative strength −46%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $2 › 200d $2 — 200d above 50d

Institutional flow Distributing

29 of 34 funds reported for Sep 30 · net -880.5K sh shares · +4 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.02% of shares out · ▼ -17.2% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

34 holders — mid 3-yr range

Squeeze score 31

low risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 57%

annualized · 1-yr

Max drawdown −65%

past year

ATR 4.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−35% Bearish

Price vs 50-day avg

−1% Neutral

RSI (14)

48 Neutral

MACD trend

Positive Bullish

52-week position

9% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $2 › 200d $2 — 200d above 50d

Institutional flow Distributing

29 of 34 funds reported for Sep 30 · net -880.5K sh shares · +4 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.02% of shares out · ▼ -17.2% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

34 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $2 · 9% Range high $4

vs 200-day avg -35% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
EVO Evotec SE this stock	$561.51M	-48.7%	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$68.47B	+37.5%	—	—	0.1%
GALDY Galderma Group AG	$53.23B	+10.1%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$51.92B	+42.6%	+4.3%	101.1	2.4%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd.	$40.66B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

27

% held: 0.7%
Reported: 29 of 34
Top holder: DCF Advisers, LLC

Held Float

View

Held by Funds

Fund positions

2

View

Short & Settlement

Short Interest Falling

Shares short

63.3K

Days to cover: 1.0d
Change: -13.2K sh

View

Short Volume

Short vol %

31%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

3.0K

Value: $4.1K
As of: Oct 13, 2026

View

Off-Exchange

Off-exchange %

52.3%

Week of: Oct 5, 2026

Off-exch Lit

View

Filings

SEC Filings

Latest

6-K

Filed: Nov 5, 2026
This year: 25

Evotec SE reported nine-month 2026 revenue of €465.0 million, down 13.1% from €535.1 million, while reaffirming full-year 2026 revenue guidance of €570 to €610 million and adjusted Group EBITDA of -€105 to -€70 million. Horizon transformation is ahead of plan.

View

Earnings & Events

Webcasts Upcoming

Next webcast

Dec 3, 2026

Last webcast: Nov 5, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
EVO	-6.5%	+14.5%	-45.7%	+3.3%	-48.7%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-9.1%	+15.7%	-46.2%	+3.5%	-59.3%

EVO · Evotec SE

Price & Indicators

Up next

Latest documents

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance